Søren Møller

Søren joined Novo Holdings A/S in 2011 as Managing Partner of Seed Investments. In his role as Managing Partner Søren is responsible for Nordic therapeutic investments, REPAIR Impact Fund and Novo Holdings’ quantum investments. Søren obtained his MSc degree from the Technical University of Denmark in 1993 and his PhD degree in molecular biology in 1997 from the Technical University of Denmark. In addition, Søren has academic training as postdoctoral fellow at Stanford University School of Medicine.

Prior to joining Seed Investments, Søren served as Global Manager of Genomics at Novozymes. Before Novozymes, Søren was CSO and Vice President of R&D at Exiqon A/S. During Søren’s tenure, Exiqon completed an IPO and the company was acquired by Qiagen in 2016. Previously, Søren worked in cancer drug development as Head of Lead Identification at BioImage and as research scientist at Novo Nordisk. Søren serves on the Board of Directors of Reapplix, Sidera Bio, Orbis Medicines and Northsea Therapeutics. Since 2008, Søren has also been board member of Danish Biotech (the Association of Biotechnology Industries in Denmark) and Active Owners Denmark.